Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Resistant hypertension and aldosterone: an update.

Clark D 3rd, Ahmed MI, Calhoun DA.

Can J Cardiol. 2012 May;28(3):318-25. doi: 10.1016/j.cjca.2012.03.010. Epub 2012 Apr 21. Review.

PMID:
22521297
2.

Resistant hypertension and hyperaldosteronism.

Gonzaga CC, Calhoun DA.

Curr Hypertens Rep. 2008 Dec;10(6):496-503. Review.

PMID:
18959838
3.

Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.

Gaddam KK, Pratt-Ubunama MN, Calhoun DA.

Expert Rev Cardiovasc Ther. 2006 May;4(3):353-9. Review.

PMID:
16716096
4.

The role of aldosterone antagonists in the management of resistant hypertension.

Nishizaka MK, Calhoun DA.

Curr Hypertens Rep. 2005 Oct;7(5):343-7. Review.

PMID:
16157075
5.

Recent advancements in the treatment of resistant hypertension.

Clark D 3rd, Guichard JL, Calhoun DA, Ahmed MI.

Postgrad Med. 2012 Jan;124(1):67-73. doi: 10.3810/pgm.2012.01.2519. Review.

PMID:
22314116
6.

Evaluation and pharmacologic approach to patients with resistant hypertension.

Adams M, Bellone JM, Wright BM, Rutecki GW.

Postgrad Med. 2012 Jan;124(1):74-82. doi: 10.3810/pgm.2012.01.2520. Review.

PMID:
22314117
7.

Resistant hypertension and aldosteronism.

Pimenta E, Calhoun DA.

Curr Hypertens Rep. 2007 Nov;9(5):353-9. Review.

PMID:
18177580
8.

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA.

J Hum Hypertens. 2010 Aug;24(8):532-7. doi: 10.1038/jhh.2009.96. Epub 2009 Dec 17.

9.

Clinical characteristics of patients with resistant hypertension: the RESIST-POL study.

Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P, Klisiewicz A, Michałowska I, Warchoł E, Januszewicz M, Kała M, Witkowski A, Więcek A, Narkiewicz K, Somers VK, Januszewicz A.

J Hum Hypertens. 2013 Nov;27(11):678-85. doi: 10.1038/jhh.2013.32. Epub 2013 May 23.

PMID:
23698004
10.

Update on diagnosis and treatment of resistant hypertension.

Pimenta E.

Iran J Kidney Dis. 2011 Jul;5(4):215-27. Review.

11.

Use of aldosterone antagonists in resistant hypertension.

Calhoun DA.

Prog Cardiovasc Dis. 2006 May-Jun;48(6):387-96. Review.

PMID:
16714158
12.

Resistant hypertension, obstructive sleep apnoea and aldosterone.

Dudenbostel T, Calhoun DA.

J Hum Hypertens. 2012 May;26(5):281-7. doi: 10.1038/jhh.2011.47. Epub 2011 Jun 9. Review.

13.

Normokalemic hyperaldosteronism in patients with resistant hypertension.

Benchetrit S, Bernheim J, Podjarny E.

Isr Med Assoc J. 2002 Jan;4(1):17-20.

14.

Mechanisms and treatment of resistant hypertension.

Pimenta E, Gaddam KK, Oparil S.

J Clin Hypertens (Greenwich). 2008 Mar;10(3):239-44.

15.

Sleep apnea, aldosterone, and resistant hypertension.

Pimenta E, Calhoun DA, Oparil S.

Prog Cardiovasc Dis. 2009 Mar-Apr;51(5):371-80. doi: 10.1016/j.pcad.2008.02.004. Review.

PMID:
19249443
16.

Aldosteronism and resistant hypertension.

Acelajado MC, Calhoun DA.

Int J Hypertens. 2011 Jan 20;2011:837817. doi: 10.4061/2011/837817.

17.

Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.

Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA.

J Hypertens. 2016 May;34(5):1005-10. doi: 10.1097/HJH.0000000000000870.

PMID:
26886564
18.

Obstructive sleep apnea and hypertension.

Calhoun DA.

Curr Hypertens Rep. 2010 Jun;12(3):189-95. doi: 10.1007/s11906-010-0112-8. Review.

PMID:
20424946
19.

Hyperaldosteronism as a common cause of resistant hypertension.

Calhoun DA.

Annu Rev Med. 2013;64:233-47. doi: 10.1146/annurev-med-042711-135929. Epub 2012 Oct 22. Review.

PMID:
23092384
20.

Resistant hypertension: who and how to evaluate.

Acelajado MC, Calhoun DA.

Curr Opin Cardiol. 2009 Jul;24(4):340-4. doi: 10.1097/HCO.0b013e32832bc6b5. Review.

PMID:
19395953

Supplemental Content

Support Center